Safety and Acceptability of Carraguard™ Among HIV-Negative Couples in Thailand - Full Text View

Sponsor:	Population Council
Collaborators:	Centers for Disease Control and Prevention Ministry of Health, Thailand Chiang Rai Public Health Office Chiang Rai District Health Office Chiang Rai Municipal Health Office Chiang Rai Hospital Bill and Melinda Gates Foundation
Information provided by:	Population Council
ClinicalTrials.gov Identifier:	NCT00213057

Purpose

The primary aims of the study were to assess the safety and acceptability of Carraguard applied vaginally prior to sexual intercourse for six months in both women and men; and to examine several dimensions of acceptability. Secondary aims were to gauge reactions to a non-contraceptive microbicide, to assess use dynamics among Thai couples and to observe preliminary indications of sexually transmitted infections and reproductive tract infections averted.

The hypothesis was that Carraguard would cause little or no significant irritation, including lesions; and that women and men would find Carraguard acceptable.

Condition	Intervention	Phase
HIV Infections Chlamydia Trachomatis Nesseria Gonorrhea Trichomonas Vaginitis Syphilis	Drug: Carraguard (PC-515)	Phase I

Study Type:	Interventional
Study Design:	Allocation: Randomized Endpoint Classification: Safety Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Prevention
Official Title:	A Randomized, Placebo-Controlled, Double-Blind Trial to Assess Expanded Safety and Acceptability of Carraguard™ (PC-515) Vaginal Gel Among Heterosexual Couples in Chiang Rai

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: Chlamydia Infections Gonorrhea HIV/AIDS Sexually Transmitted Diseases Syphilis Trichomoniasis

U.S. FDA Resources

Further study details as provided by Population Council:

Primary Outcome Measures:

Safety (toxicity/local irritation): Genital exam and interview for signs and symptoms, 14-days after enrollment and monthly thereafter for 6 months; testing for bacterial vaginosis and candida (women) and balanitis (men) monthly.
Acceptability: Interview about gel use to assess compliance (monthly) and acceptability (quarterly).

Secondary Outcome Measures:

Preliminary effectiveness: Swabs taken from women an urine specimens collected from men to test for sexually transmitted infections – gonorrhea, chlamydia, trichomoniasis (monthly) and for genital ulcer disease, if ulceration was detected; blood drawn

Estimated Enrollment:	110
Study Start Date:	June 2001
Estimated Study Completion Date:	June 2002

Detailed Description:

Carraguard™ (PC-515), the Population Council’s lead candidate microbicide, was tested in a triple-masked, randomized, placebo-controlled trial fielded in one site in Chiang Rai, northern Thailand. The primary aims of the study were to assess Carraguard’s safety (toxicity) in both men and women – including signs of local irritation, such as itching or burning; changes in vaginal flora (women); and incidence of abnormal external genital, vaginal (women), and cervical findings (women) – when applied vaginally prior to intercourse for 6 months; to evaluate acceptability; to gauge men’s and women’s reactions to a non-contraceptive microbicide; and to explore microbicide use dynamics in a Thai population.

Secondary aims were to investigate sexually transmitted infections averted – including HIV, C. trachomatis, N. gonorrhoeae, T. vaginalis, and T. pallidum (preliminary indications) in men and women; bacterial vaginosis and candidaisis in women; and balanitis in men; and effect on cervical cytology.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

· In good health,
- Aged 18 years or older,
- Resident for at least 1 year; planning to stay for at least 12 months,
- HIV-seronegative and free of all other STD at initial screening exam,
- No reported sex partners other than current partner for prior year and and not planning on having any other sex partners for the duration of the study,
- Not using condoms routinely (>25% of the time) in the prior year
- Willing and able to comply with the study protocol (including being tested for HIV, learning the results, agreeing to partner notification if a curable STD is diagnosed, and undergoing clinical evaluations),
- Able to achieve a score of 80% or better on true-false test of key study concepts, and
- Able to give informed consent.
- Planning to have vaginal sexual intercourse together on average at least once per week during the next six months.

Exclusion Criteria:

· Pregnant or desire to become pregnant at time of study participation,
- Delivered or aborted a pregnancy within the six weeks prior to screening,
- Male sex partner known at enrollment to be HIV positive,
- History of surgery on external genitalia, vagina or cervix in the six weeks prior to screening,
- Recent history of non-menstrual vaginal bleeding with intercourse,
- Clinically detectable genital abnormality (including presence of warts, or a structural or congenital abnormality),
- Genital epithelial disruption; men/women with healed lesions (intact epithelium) will be eligible,
- Untreated symptomatic bacterial vaginosis or candidiasis. Women with asymptomatic BV or yeast may be enrolled. Women with treated symptomatic BV or candidaisis may be enrolled once no longer symptomatic. Women with signs or laboratory evidence of BV or candidaisis may be enrolled if they are asymptomatic. Women with symptoms of vaginal infection may be enrolled only if their enrollment visit stat laboratory evaluation is negative for BV, candidaisis or trichomoniasis,
- Presence of balanitis. Men with resolved balanitis (e.g. through treatment) will be eligible,
- Abnormal Pap smear (Class II or above),
- History of sensitivity/allergy to latex,
- Concurrent participation in another trial of a vaginal product,
- Injection of recreational drugs.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00213057

Locations

Thailand
Chiang Rai Health Club
Chiang Rai, Thailand, 57001

Sponsors and Collaborators

Population Council

Centers for Disease Control and Prevention

Ministry of Health, Thailand

Chiang Rai Public Health Office

Chiang Rai District Health Office

Chiang Rai Municipal Health Office

Chiang Rai Hospital

Bill and Melinda Gates Foundation

Investigators

Principal Investigator:

Kelly Blanchard, MSc

Population Council

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00213057 History of Changes
Other Study ID Numbers:	Population Council #270, CDC Protocol #2968
Study First Received:	September 13, 2005
Last Updated:	December 21, 2005
Health Authority:	United States: Food and Drug Administration; Thailand: Food and Drug Administration

Keywords provided by Population Council:

Microbicides
HIV prevention
sexually transmitted infections
carrageenan

sero-concordant couples
HIV Seronegativity
HIV

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Chlamydia Infections
Gonorrhea
Syphilis
Trichomonas Infections
Trichomonas Vaginitis
Vaginitis
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes

Immune System Diseases
Slow Virus Diseases
Chlamydiaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Sexually Transmitted Diseases, Bacterial
Infection
Genital Diseases, Male
Genital Diseases, Female
Neisseriaceae Infections
Treponemal Infections
Spirochaetales Infections
Protozoan Infections
Parasitic Diseases
Vaginal Diseases

ClinicalTrials.gov processed this record on February 09, 2012